Celcuity Inc. (NASDAQ:CELC) is a biotechnology company focused on developing diagnostic tests that provide insights into the cellular activity of cancer patients. This helps in identifying the most effective therapies for individual patients. The company operates in a competitive landscape alongside other biotech firms like Crinetics Pharmaceuticals, Evelo Biosciences, Scholar Rock Holding Corporation, and Cue Biopharma.

Celcuity's Return on Invested Capital (ROIC) is -36.46%, which is significantly lower than its Weighted Average Cost of Capital (WACC) of 4.88%. This negative ROIC indicates that Celcuity is not currently generating positive returns on its invested capital. The ROIC to WACC ratio of -7.47 further highlights that the company's returns are well below its cost of capital.

In comparison, Crinetics Pharmaceuticals has a ROIC of -42.35% and a WACC of 4.55%, resulting in a ROIC to WACC ratio of -9.30. Although Crinetics also has a negative ROIC, its ratio is the least negative among the peers, suggesting it is relatively closer to covering its cost of capital than Celcuity.

Evelo Biosciences presents a more challenging scenario with a ROIC of -201.37% and a WACC of 9.04%, leading to a ROIC to WACC ratio of -22.28. This indicates that Evelo is far from generating returns that meet its cost of capital, a situation more severe than that of Celcuity.

Scholar Rock Holding Corporation and Cue Biopharma also show negative ROICs of -101.98% and -151.57%, respectively, with ROIC to WACC ratios of -15.01 and -15.31. These figures reflect the common trend among clinical-stage biotech companies, which often face negative returns due to high R&D investments and limited revenue generation at this stage.